{"name":"Beta Pharma (Suzhou) Co., Ltd.","slug":"beta-pharma-suzhou-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPTXMzalVsd0VQa0V6cGxWTDFvZEpMRHVrMXB4eUhlS001eUpMN1hGSUpRZ25RVUlHX2FfSUxFZnV4UkZNR0N4RGRuckJWTkNHcXJ3dEs4Zy1uRm41bVQyNlE1NEgxNS00OFB4eWNnTlVIQ01NYjBCaERJUzgtVXhZWWxzQThiTkFsLS1Ibjg4dEtydW81THg0U0l2b29pNEZvc3UyMk9fOHJjQQ?oc=5","date":"2026-04-07","type":"trial","source":"Yahoo Finance","summary":"Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight - Yahoo Finance","headline":"Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxORnNvOVNBU2gwN05TRFlyRnhVYkJjYngxTjVQd0V1SUJtcl9yZHhTVUtDNlpMeGdJalQxRGx5T0RReU96ZFNjSWxjaElkSjQzdmZEalVBeld3R21BMzlhd09vVlhwQ005S0trLXNUODRoUm5yckRhc1ZqMEdjZUtjT2c3WFZBQ0NSUmEtNngwZU14bjFrUjhSamZnbHlsVHFwZW4tWnROWTBZRlUtbFVLZXZ2czRPR0Rxd0EzbWwtbFFJUjc0UzYxdTJYaUNNYjduTHBodmZrZnZsN0pDSFE?oc=5","date":"2026-02-17","type":"trial","source":"Citeline News & Insights","summary":"Phase III Adjuvant Lung Cancer Success For Lilly’s Retevmo - Citeline News & Insights","headline":"Phase III Adjuvant Lung Cancer Success For Lilly’s Retevmo - Citeline News & Insights","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNWkpSUmdEVXNISWNIcXpySTZwWnRwdWdWOS1VajZudnA0eG9nX3dJMHc0Y2Z5VHY0Q1JCWTAycnZQaTEySm5xdjFKMExKcjBZcXJWelhDM3dMU09UUjZHR0xReXQ1WUthTXQ2UTBWVVp5b1VQYmRsb1p1N3RlVnNGWVZyLXUwZ1M3VXRoVmF1anl0UUY3?oc=5","date":"2026-02-12","type":"pipeline","source":"finviz.com","summary":"MDGL Strengthens MASH Franchise With New Genetic Approaches - finviz.com","headline":"MDGL Strengthens MASH Franchise With New Genetic Approaches","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxQd2FISzFkSVRnaUk4SVpxVnNZaWpCU3FVdVVIOUt6YnFDTmloSG5mTWxhTVVRV3FBRlEtM1J0aGhJUDVaZW5pblZ4cjZYSHZpX3NnSWFHVGJCU2JjbUVPUk9nZUJudHFSTnkzMGJyT2Q2QUFKQVpCN1l6SnZjSWhFeERyQ3Y4OTJadExYeUtlLTBPU21WZVU1QzVRLVFyU0dzeUxpVnZKZ2YxOHVZeW04ZFlsYndTLTFDMWFkMmF0RG9QVVZMZzRsaGhWbk1zNFVaZVc0b24zUlowcGNBdVhWb19IejI0a2pXU1YyQ1AzdG1QUmNlVGxhRFBrSGNaay1CQ0w4RGNraUs?oc=5","date":"2026-02-11","type":"pipeline","source":"PR Newswire","summary":"Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH - PR Newswire","headline":"Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MAS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAJBVV95cUxOUkwzWE45aWVXRDBsemE3WFQwZ2huVEVZWkRnclZ3S2NkcmNMcWdYQW9KZWRWNzYyX2xwRVVjb0F4V1JxZHJuSVJrNFV0WDFJMlVpUGJQMzRFLWhUVW5raUJfNjFuczJlM1lRaVlXYnp4Zndxbkd1M253LS1EMnEyYUxndlVCUFM1ZGota2dKd0U4UjJHV3ZmN3IwaGpKZHB0am1QWjhTbjVCWXRHNFpnb1dBd2FZYjA1bFpOVFNLbG9zXzdwcXk1dHBtTWI1Z2hvNHlySzFuQ1gtMjhIZlZZbE1kME1vS01NRDF2SFp4c3hXcEJWeFBoWUNFQXZHTGtkakd2TDJZSUZTRmdUOVFrcQ?oc=5","date":"2026-02-11","type":"pipeline","source":"GlobeNewswire","summary":"Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs - GlobeNewswire","headline":"Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNTTFKcFVYZGc5UXhCMTZ6X0Rmc0ZldkxoeDlETzRlT0JQS0ltN0RZdE52Y0UtWFVKdzc4d3pEdG1fWGVtdXVlcmJ3MlNlTktWcWw0cHRycFlqS0tkdzlVb2hOTVZWcHJLS0NOLWhBcDJmU3VsNGpPaXNsNDJtMUJuZG9BZUMyZUpxdlE5YVFxUEo3TVZ4d2lpV0x2MGpVWHlnOG9wdENLa2lCNjMwd3ZiZzBzMEdHRDFPVjRZY3NHdG4?oc=5","date":"2026-02-11","type":"pipeline","source":"Stock Titan","summary":"Madrigal signs RNA liver drug pact with Ribo worth up to $4.4B - Stock Titan","headline":"Madrigal signs RNA liver drug pact with Ribo worth up to $4.4B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxNRG12S3NpMEktUmxVUjBCdlhJRFljTjNZbUhFVkZWd05OcVVvTFFNTVdUSDNzTW1BMHQ3U3VjejB1bGlSYTAzQ3k4OFZSa1Q3dHBMbDB1LXRQZHh3Tjl1YVB6LV9hakhBM1BudWRKT3NIOUYtY0t2TUJoWFl4ZHgzUkdwb0g4U2xncEtJOEQ5OExrZVNWT051YTF0QTQwU3lFSFczNS1kZDhwZjZZdnUyRHR1YTU0UVBWZHRDbVJxcDRGU3N4SUxNNGs5Yk90V3JGbEhrRzc3dENOeVlDNC1NVEJWS3hOckZZUkYtaXRPX1RwdWRiTmZib21QcVpJYWM?oc=5","date":"2026-01-13","type":"deal","source":"Citeline News & Insights","summary":"Asia Deal Watch: Eisai Obtains Rights To Nuvation’s Ibtrozi Outside US, Japan, China - Citeline News & Insights","headline":"Asia Deal Watch: Eisai Obtains Rights To Nuvation’s Ibtrozi Outside US, Japan, China - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPWnBBVVNCOTRsbkFOYWpTdTVJM1pVOWlfbGR1SktLM1NSakl0eUdHNEtsOXJKNFhRblhleFNtak1ES3dPNzBtVFpuTEpTY21renVjdnVaMlRWckZBTlVPemczNVdheVJ6aWJQZ1J4Rm0zN01QNTVJeEhqVjM1UTJIZXZ2dF9VeGRCOEl3Vnotb1JmczkzYm9SdnlCZGZLQ1ds?oc=5","date":"2025-12-23","type":"deal","source":"BioWorld News","summary":"China-made products account for 30% of global deals in 2025 - BioWorld News","headline":"China-made products account for 30% of global deals in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxQMkFqR3R5Mmw4WWdUTWVvN0xYM3R4YjVta1RrN0hZSnlNci02aHUtM2FVWEY3TXB2bDk2bEU5Sy1FOVZBZ0JScmtLdjZMc2lfMU9WNVIxblVBSkt2ZGFrNjVsdVNoU0RoS1o0MU9wNnh3RU84ZFJYWVFld1NmY3l2UmtRNnhJdFVpbnNneGhlQWwyNnpKa1Fyak1wVmNiTVgzUjNPdFhLZ0xIZF9FclItdmt0cG02UlVGM1pSdWEtZ2NZTUZWMEYySlJSbk82R090X0ZaZWw0dzluYVhkS3kzTXJTZTBySmJHNXFIcWF4QUNrQXY0UW9ROVhwaVVjTDFUUEhFMHAtaldMemhHTC1kOUVKRmZnRWFKaXZoRm1hOA?oc=5","date":"2025-08-14","type":"trial","source":"GlobeNewswire","summary":"Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma - GlobeNewswire","headline":"Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAJBVV95cUxPMk1Rb0pjOUY4WXAtZTVRY0hWUFN1RzluZFVXcHBoMmhxaG45QktTZ2pkWnhYQjBKTWxkalFzbXQ0NE41N0lOVTB6UWZrUHh4ZTIzX1BYNUxqZHdSc0lHLWZWNjhGVjNQekJCeGZfLXE0X2syTUQ2UjZXOEloN25rOG9aeGdKV042UHV6NXJNR0tTRzRwSzBxRGlzMWtzQjJsOGt4bWt6Y1NkN25zUXpIc2ZscFZXQ3Z4YUJVMjdXUG85RWVzWkY5Q0ZaU2ZVM2lpSDF6RGh6c3V1cjRlckNtd09OdDBoQlRRWDY3cWhJdUliMEFnU2lKMEFoMXVLOUtMNU1LNGMydm40TEZaeVBpMGxLWWJvbk5rS1hIYzg2VWVraW43a3BQbFlLZ25zRkpZakdDTg?oc=5","date":"2025-08-11","type":"regulatory","source":"Barchart.com","summary":"Hearing Loss Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | Sensorion, Fennec Pharma, Sound Pharma, Decibel Therapeutics, Akouos - Barchart.com","headline":"Hearing Loss Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | Sensorion, Fenn","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQVHI4MG5idDZaMUVwODRYVXZIcEhlbFlOaFpvQkVVaDdwNFMzYmdURWlkY3JHM01LX2dSY01HdXU3MG9wYjFtSUcyU2VGVGd6amJYc2tnQVpEd3R0dlE2aHhLMEF1ZXFYN29OVlRldzYtd25VdmtWWjE4a1RJNFZKbXpwNGU4ZGxDc0lmdmY1LWFTSkRmNi1TU05wTQ?oc=5","date":"2025-06-03","type":"pipeline","source":"BioWorld News","summary":"Astellas nabs Evopoint’s CLDN18.2-targeting ADC for $1.34B - BioWorld News","headline":"Astellas nabs Evopoint’s CLDN18.2-targeting ADC for $1.34B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE1WN3hBRmg1WUp2bWRhZHhXQ2Zyc19KRXAxLWxtak96Q1BkaVJtenh3clI2WkwyaURVQXBLQXFBYURLcHBIUVNVaTFTTm5OMl9sLXVSb1RtY3JzbS0wc3RZWENzUEVrdDlONEhZVHBUWmRMTGlSWnBFWFRQSEM?oc=5","date":"2024-05-01","type":"pipeline","source":"jnm.snmjournals.org","summary":"Landscape of Nuclear Medicine in China and Its Progress on Theranostics - jnm.snmjournals.org","headline":"Landscape of Nuclear Medicine in China and Its Progress on Theranostics","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}